Coforge: Q2 FY27 Revenue Climbs 40.1% to $652.2 Million

Coforge announced its financial results for the second quarter of fiscal year 2027 (Q2 FY27), ending September 30, 2026. The company reported a substantial 40.1% year-over-year growth in revenue, reaching $652.2 million. Key financial highlights include a 53.0% YoY increase in EBIT and a 42.7% YoY rise in PAT. Coforge also upgraded its FY27 consolidated EBIT margin guidance to 16.0%, reflecting continued growth momentum and improved profitability.

Coforge Reports Strong Q2 FY27 Financials

Coforge Limited has unveiled its financial performance for the second quarter of fiscal year 2027 (Q2 FY27), which concluded on September 30, 2026. The company demonstrated robust growth across key financial metrics, signaling a positive trajectory for the fiscal year.

Revenue and Profitability Growth

In Q2 FY27, Coforge’s revenue stood at $652.2 million, marking a significant 40.1% increase year-over-year (YoY) and a 10.1% rise quarter-over-quarter (QoQ). Organic CC growth was reported at 3.8% QoQ. The company’s profitability also saw considerable improvement, with EBIT increasing by 53.0% YoY to $104.1 million. Profit After Tax (PAT) surged by 42.7% YoY to $62.2 million, and Earnings Per Share (EPS) grew by 18.3% YoY.

Upgraded Margin Guidance

A key highlight from the announcement is the upgraded guidance for the full fiscal year 2027. Coforge has raised its consolidated EBIT margin guidance to 16.0%, up from the previous forecast of 15.5% to 16.0%. This upward revision underscores the company’s confidence in its operational efficiency and market positioning.

Key Financial Metrics Overview

  • Revenue: $652.2 Mn (+40.1% YoY)
  • EBIT Margin: 16.0% (+134 bps YoY)
  • EBIT: $104.1 Mn (+53.0% YoY)
  • PAT: $62.2 Mn (+42.7% YoY)
  • EPS: ₹13.3 (+18.3% YoY)
  • FCF: $53.8 Mn
  • FCF/PAT: 89% in Q2FY27

The company also noted healthy Free Cash Flow (FCF) conversion at 89% of PAT, compared to 86% in Q2 FY26.

Source: BSE

Previous Article

Gland Pharma: USFDA Inspection at Formulation Facility Concludes with 4 Observations

Next Article

Neptune Logitek: Appoints New Independent Director, Reconstitutes Committees